Comparison of Survival Outcomes Between Clinical Trial Participants and Non-participants of Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Cohort Study

Overview

Journal Heliyon

Specialty Social Sciences

Date 2023 Dec 11

PMID 38076123

Authors

Qingqing Jiang

Xiaolin Yue

Haike Lei

Weiran Mao

Yongsheng Li

Xia Chen

Affiliations

Soon will be listed here.

Abstract

Background: Clinical trials for advanced non-small cell lung cancer (NSCLC) have been conducted extensively. However, the effect of participation in clinical trials on survival outcomes remains unclear. This study aimed to assess whether participation in clinical trials was an independent prognostic factor for survival in patients with advanced NSCLC.

Methods: We analyzed the medical records of patients aged ≥18 years who were newly diagnosed with stage IIIB or IV NSCLC and received chemotherapy or immunotherapy from September 2016 to June 2020 in this retrospective cohort study. To reduce the impact of confounding factors, propensity score matching (PSM) was performed. The Kaplan-Meier method and log-rank test were used to calculate and compare the overall survival (OS) and progression-free survival (PFS) of the patients. Finally, Cox proportional hazards regression was employed to examine the correlation between clinical trial participation and survival outcomes.

Results: The study enrolled 155 patients in total, of which 62 (40.0 %) patients participated in NSCLC clinical trials. PSM identified 50 pairs of patients in total. The median PFS and OS of clinical trial participants and non-participants were 17.2 vs. 13.9 months ( = 0.554) and 32.4 vs. 36.5 months ( = 0.968), respectively. According to the results of multivariate Cox proportional hazards regression analysis, clinical trial participation was not an independent prognostic factor for advanced NSCLC patients (: 0.89, 95 % : 0.50-1.61; = 0.701).

Conclusions: The clinical trial participants with advanced NSCLC displayed similar survival outcomes compared with the non-participating patients in this cohort.

Citing Articles

A comprehensive nomogram for assessing the prognosis of non-small cell lung cancer patients receiving immunotherapy: a prospective cohort study in China.

Li H, Yuan Y, Xu Q, Liang G, Hu Z, Li X Front Immunol. 2024; 15:1487078.

PMID: 39635526 PMC: 11614804. DOI: 10.3389/fimmu.2024.1487078.

References

Tsakiridis T, Pond G, Wright J, Ellis P, Ahmed N, Abdulkarim B . Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. JAMA Oncol. 2021; 7(9):1333-1341. PMC: 8323053. DOI: 10.1001/jamaoncol.2021.2328. View

Liu J, Hou W, Gonen M, Seluzicki C, Li S, Mao J . Symptom burden and willingness to participate: implications for herbal clinical trials in lung cancer. Ann Palliat Med. 2020; 10(2):1895-1903. PMC: 9297344. DOI: 10.21037/apm-20-865. View

Ma S, Tang X, Long L, Bai X, Zhou J, Duan Z . Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology. 2021; 10(1):1909296. PMC: 8078693. DOI: 10.1080/2162402X.2021.1909296. View

Han J, Kim J, Suh K, Kim J, Kim S, Kim Y . Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. Asia Pac J Clin Oncol. 2019; 15(3):158-165. DOI: 10.1111/ajco.13145. View

Grosu H, Manzanera A, Shivakumar S, Sun S, Noguras Gonzalez G, Ost D . Survival disparities following surgery among patients with different histological types of non-small cell lung cancer. Lung Cancer. 2019; 140:55-58. DOI: 10.1016/j.lungcan.2019.12.007. View

Arrieta O, Carmona A, Ramirez-Tirado L, Flores-Estrada D, Macedo-Perez E, Martinez-Hernandez J . Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials. Oncology. 2016; 91(4):185-193. DOI: 10.1159/000447404. View

Zhong Q, Tao Y, Chen H, Zhou Y, Huang L, Han X . The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020. Lancet Reg Health West Pac. 2021; 11:100151. PMC: 8315452. DOI: 10.1016/j.lanwpc.2021.100151. View

Nielsen Z, Berthelsen C . Cancer patients' perceptions of factors influencing their decisions on participation in clinical drug trials: A qualitative meta-synthesis. J Clin Nurs. 2019; 28(13-14):2443-2461. DOI: 10.1111/jocn.14785. View

Wang Y, Li C, Wang Z, Wang Z, Wu R, Wu Y . Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. BMC Med. 2022; 20(1):426. PMC: 9641944. DOI: 10.1186/s12916-022-02580-1. View

10.

Takeuchi E, Kondo K, Okano Y, Kunishige M, Kondo Y, Kadota N . Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer. J Cancer Res Clin Oncol. 2022; 149(7):3139-3147. PMC: 10314836. DOI: 10.1007/s00432-022-04215-7. View

11.

Nielsen Z, Eriksson S, Schram Harslof L, Petri S, Helgesson G, Mangset M . Are cancer patients better off if they participate in clinical trials? A mixed methods study. BMC Cancer. 2020; 20(1):401. PMC: 7206768. DOI: 10.1186/s12885-020-06916-z. View

12.

Wu Y, Wu H, Lin M, Liu T, Li J . Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients. Transl Oncol. 2021; 15(1):101268. PMC: 8605342. DOI: 10.1016/j.tranon.2021.101268. View

13.

Field K, Drummond K, Yilmaz M, Tacey M, Compston D, Gibbs P . Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset. J Clin Neurosci. 2013; 20(6):783-9. DOI: 10.1016/j.jocn.2012.09.013. View

14.

Xu X, Li R, Zhu P, Zhang P, Chen J, Lin Y . Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World J Surg Oncol. 2021; 19(1):231. PMC: 8349029. DOI: 10.1186/s12957-021-02340-0. View

15.

Liang S, Zhou G, Hu W . Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer. Int J Mol Sci. 2022; 23(4). PMC: 8876478. DOI: 10.3390/ijms23042316. View

16.

Yaung S, Woestmann C, Ju C, Ma X, Gattam S, Zhou Y . Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers (Basel). 2022; 14(10). PMC: 9139958. DOI: 10.3390/cancers14102479. View

17.

Yang G, Ong W, Tan J, Ding J, Ho S, Tan D . Motivations and experiences of patients with advanced cancer participating in Phase 1 clinical trials: A qualitative study. Palliat Med. 2022; 37(2):257-264. DOI: 10.1177/02692163221137105. View

18.

David E, Andersen S, Beckett L, Melnikow J, Clark J, Brown L . Survival benefits associated with surgery for advanced non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018; 157(4):1620-1628. PMC: 6448577. DOI: 10.1016/j.jtcvs.2018.10.140. View

19.

Merkhofer C, Eaton K, Martins R, Ramsey S, Goulart B . Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021; 22(6):523-530. PMC: 8531178. DOI: 10.1016/j.cllc.2021.04.003. View

20.

Popat V, Lu R, Ahmed M, Park J, Xie Y, Gerber D . Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. Oncologist. 2020; 25(6):515-522. PMC: 7288632. DOI: 10.1634/theoncologist.2019-0814. View